The Role of Iron and Other Factors in Patients Unresponsive to Erythropoietin Therapy
- 1 January 1995
- journal article
- Published by Wiley in Seminars in Dialysis
- Vol. 8 (1) , 29-34
- https://doi.org/10.1111/j.1525-139x.1995.tb00324.x
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Effect of Serum Parathyroid Hormone and Bone Marrow Fibrosis on the Response to Erythropoietin in UremiaNew England Journal of Medicine, 1993
- A comparison of the responses to recombinant human erythropoietin in normal and uremic subjectsKidney International, 1992
- RACTICAL GUIDELINES FOR DRUG THERAPY IN DIALYSIS George R. Aronoff, Series Editor: Iron Dextran in Chronic Renal FailureSeminars in Dialysis, 1991
- Erythropoietin Treatment of Anemia Associated with Multiple MyelomaNew England Journal of Medicine, 1990
- Recombinant Human Erythropoietin for Patients with AIDS Treated with ZidovudineNew England Journal of Medicine, 1990
- Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.BMJ, 1990
- Erythropoietin, aluminium, and anaemia in patients on haemodialysisThe Lancet, 1990
- Treatment of the Anemia of Progressive Renal Failure with Recombinant Human ErythropoietinNew England Journal of Medicine, 1989
- Plasma aluminum is bound to transferrinLife Sciences, 1983
- Effect of parathyroid hormone on erythropoiesis.Journal of Clinical Investigation, 1981